KA
CYCN icon

Kovack Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Kovack Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5K Buy
+10,000
New +$14.2K ﹤0.01% 1008

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Kovack Advisors's CYCN Position: Q1 2026 in Review

Kovack Advisors opened a new position in Cyclerion Therapeutics (CYCN) in Q1 2026: 10,000 shares worth $15.5K. The stake represents ﹤0.01% of the portfolio and ranks #1008 among its holdings.

17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Kovack Advisors held 10,000 shares of Cyclerion Therapeutics worth $15.5K as of Q1 2026.
  • Cyclerion Therapeutics was a new Kovack Advisors position in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of Kovack Advisors's portfolio in Q1 2026, its #1008 holding.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.